Galderma Group AG

SWX:GALD Stock Report

Market Cap: CHF 36.1b

Galderma Group Valuation

Is GALD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GALD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: GALD (CHF154.95) is trading below our estimate of future cash flow value (CHF303.49)

Significantly Below Future Cash Flow Value: GALD is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GALD?

Key metric: As GALD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GALD. This is calculated by dividing GALD's market cap by their current earnings.
What is GALD's PE Ratio?
PE Ratio51.3x
EarningsUS$863.00m
Market CapUS$44.25b

Price to Earnings Ratio vs Peers

How does GALD's PE Ratio compare to its peers?

The above table shows the PE ratio for GALD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average33x
SDZ Sandoz Group
54.7x23.95%CHF 28.9b
NOVN Novartis
20.4x10.58%CHF 213.0b
ROP Roche Holding
22.2x10.30%CHF 275.1b
DESN Dottikon ES Holding
34.5x13.30%CHF 3.6b
GALD Galderma Group
51.3x22.92%CHF 36.1b

Price-To-Earnings vs Peers: GALD is expensive based on its Price-To-Earnings Ratio (51.3x) compared to the peer average (33x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does GALD's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
GALD 51.3xIndustry Avg. 20.5xNo. of Companies10PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GALD is expensive based on its Price-To-Earnings Ratio (51.3x) compared to the European Pharmaceuticals industry average (20.5x).

Price to Earnings Ratio vs Fair Ratio

What is GALD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GALD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio51.3x
Fair PE Ratio38.9x

Price-To-Earnings vs Fair Ratio: GALD is expensive based on its Price-To-Earnings Ratio (51.3x) compared to the estimated Fair Price-To-Earnings Ratio (38.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GALD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 154.95
CHF 193.27
+24.73%
14.14%CHF 260.47CHF 128.82n/a17
Sep ’27CHF 167.10
CHF 190.51
+14.01%
13.91%CHF 257.68CHF 127.44n/a17
Aug ’27CHF 175.75
CHF 192.04
+9.27%
13.66%CHF 258.88CHF 128.03n/a18
Jul ’27CHF 178.85
CHF 188.23
+5.25%
16.07%CHF 268.18CHF 116.71n/a18
Jun ’27CHF 163.90
CHF 183.68
+12.07%
15.93%CHF 260.64CHF 113.43n/a18
May ’27CHF 163.80
CHF 182.71
+11.55%
16.33%CHF 262.12CHF 114.07n/a18
Apr ’27CHF 156.40
CHF 181.06
+15.77%
16.34%CHF 258.20CHF 115.38n/a18
Mar ’27CHF 145.90
CHF 165.34
+13.32%
14.88%CHF 191.96CHF 109.15n/a14
Feb ’27CHF 143.90
CHF 166.06
+15.40%
16.53%CHF 197.17CHF 108.13n/a15
Jan ’27CHF 162.10
CHF 159.39
-1.67%
16.21%CHF 190.19CHF 108.91n/a13
Dec ’26CHF 158.10
CHF 153.77
-2.74%
15.35%CHF 189.53CHF 110.15n/a13
Nov ’26CHF 148.50
CHF 150.26
+1.18%
14.24%CHF 185.99CHF 110.19n/a13
Oct ’26CHF 134.70
CHF 141.65
+5.16%
13.60%CHF 162.84CHF 91.89n/a12
Sep ’26CHF 139.90
CHF 139.74
-0.12%
13.02%CHF 163.49CHF 92.25CHF 167.1012
Aug ’26CHF 127.50
CHF 136.72
+7.23%
13.80%CHF 164.50CHF 92.82CHF 175.7512
Jul ’26CHF 115.50
CHF 110.41
-4.41%
11.63%CHF 129.98CHF 82.32CHF 178.8511
Jun ’26CHF 107.70
CHF 107.67
-0.024%
8.26%CHF 119.40CHF 85.47CHF 163.9011
May ’26CHF 95.90
CHF 107.36
+11.95%
7.91%CHF 115.57CHF 85.62CHF 163.8011
Apr ’26CHF 95.43
CHF 112.07
+17.44%
9.10%CHF 123.94CHF 85.93CHF 156.4011
Mar ’26CHF 109.94
CHF 108.76
-1.07%
11.00%CHF 128.06CHF 87.90CHF 145.9011
Feb ’26CHF 110.70
CHF 103.53
-6.48%
10.58%CHF 123.81CHF 84.51CHF 143.9011
Jan ’26CHF 100.64
CHF 99.84
-0.79%
7.85%CHF 109.53CHF 83.57CHF 162.1011
Dec ’25CHF 90.25
CHF 93.20
+3.27%
7.45%CHF 107.33CHF 80.47CHF 158.1011
Nov ’25CHF 81.44
CHF 89.47
+9.86%
7.90%CHF 105.52CHF 79.12CHF 148.5011
Oct ’25CHF 77.61
CHF 82.53
+6.33%
9.50%CHF 102.40CHF 72.86CHF 134.7011
Sep ’25CHF 82.30
CHF 80.01
-2.79%
7.59%CHF 90.14CHF 70.34CHF 139.9010
CHF 193.27
Fair Value
19.8% undervalued intrinsic discount
17
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 02:38
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Galderma Group AG is covered by 29 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yihan LiBarclays
James GordonBarclays
Fulvio CazzolBerenberg